Major U.S. indexes were little changed at midday Wednesday, ahead of the Federal Reserve's decision on interest rates.

Wolfe Research analyst Michael Polark downgraded the rating on Resmed (RMD – Research Report) to a Sell yesterday, setting a price target ...

Wolfe Research downgraded shares of the maker of sleep-apnea airway machines to Underperform from Peer Perform.

Wolfe Research has recently reduced Resmed Inc (RMD) stock to Underperform rating, as announced on September 18, 2024, according to Finviz. Earlier, on September 4, 2024, Needham had reduced the stock ...

ResMed Inc. closed $4.30 below its 52-week high ($255.18), which the company reached on September 9th.

ResMed achieved double-digit revenue growth through acquisitions and operating efficiencies, with improving capital ...

Healthcare technology company ResMed's (NYSE: RMD) stock wasn't quite the picture of health on Wednesday. The shares lost ...

ResMed's AirSense 11 platform and myAir app enhance patient engagement and efficiency. Check out why I remain bullish on RMD ...

In a report released today, Michael Matson from Needham maintained a Hold rating on Resmed (RMD – Research Report). The company’s ...

For example, the ResMed Inc. (NYSE:RMD) share price is 91% higher than it was five years ago, which is more than the market average. It's fair to say the stock has continued its long term trend in ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

ResMed faces a 3% drop in share price after concerns over Eli Lilly’s Ozempic, which could impact the demand for CPAP ...